CA
NZ
UK
AU
IND
US
…
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
XBiotech is a clinical-stage biotechnology company developing True Human monoclonal antibodies that target inflammatory pathways, notably interleukin‑1α, for inflammatory and oncology indications. Long-term growth may be driven by positive clinical data, regulatory approvals and partnerships, and investors may find exposure to a focused biologics platform attractive.
Principal risks include high clinical and regulatory uncertainty plus substantial capital requirements that could dilute shareholders and delay programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -45.30M | -38.56M | -24.31M | -33.59M | -25.46M |
| Net income | -45.54M | -38.53M | -24.56M | -32.90M | -17.41M |
| Selling general administrative | 8.29M | 4.71M | 4.66M | 6.30M | 9.39M |
| Selling and marketing expenses | - | - | 1.74M | - | - |
| Gross profit | -1.69M | - | -1.74M | 3.36M | 12.57M |
| Reconciled depreciation | 1.69M | 1.75M | 1.75M | 2.61M | 2.65M |
| Ebit | -45.22M | -37.76M | -24.31M | -34.49M | -25.08M |
| Ebitda | -43.53M | -36.01M | -22.57M | -29.08M | -21.72M |
| Depreciation and amortization | 1.69M | 1.75M | 1.74M | 5.41M | 3.36M |
| Non operating income net other | - | - | - | 0.90M | -0.38M |
| Operating income | -55.69M | -42.47M | -37.51M | -34.49M | -25.08M |
| Other operating expenses | 55.69M | 42.47M | 37.51M | 38.50M | 43.48M |
| Interest expense | 0.09M | 0.81M | 0.00M | -0.90M | 1.09M |
| Tax provision | 0.23M | -0.03M | 0.92M | -0.69M | -8.04M |
| Interest income | 5.68M | 9.81M | 10.29M | 3.82M | 0.47M |
| Net interest income | 5.59M | 9.01M | 10.29M | 3.82M | 0.47M |
| Income tax expense | 0.23M | -0.03M | 0.24M | -0.69M | -8.04M |
| Total revenue | 0.00M | 0.00M | 0.30M | 4.01M | 18.39M |
| Total operating expenses | 54.00M | 42.47M | 37.51M | 37.85M | 37.66M |
| Cost of revenue | 1.69M | 1.75M | 1.74M | 0.65M | 5.82M |
| Total other income expense net | 10.38M | 3.91M | 13.20M | 0.90M | -0.38M |
| Net income from continuing ops | -45.54M | -38.53M | -23.12M | -32.90M | -17.41M |
| Net income applicable to common shares | - | - | - | -32.90M | -17.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 150.08M | 199.09M | 227.24M | 246.10M | 275.18M |
| Other current assets | 1.04M | 1.03M | 0.76M | 0.60M | 9.89M |
| Total liab | 9.73M | 16.82M | 8.40M | 5.70M | 5.79M |
| Total stockholder equity | 140.35M | 182.27M | 218.85M | 240.40M | 269.38M |
| Other current liab | 6.32M | 0.91M | 3.58M | 1.66M | 1.38M |
| Common stock | 276.73M | 273.11M | 271.15M | 267.32M | 262.26M |
| Capital stock | 276.73M | 273.11M | 271.15M | 267.32M | 262.26M |
| Retained earnings | -136.38M | -90.84M | -52.31M | -27.75M | 5.15M |
| Other liab | - | - | - | 1.64M | 2.34M |
| Other assets | - | - | - | - | -0.00M |
| Cash | 125.55M | 172.68M | 200.02M | 157.31M | 236.98M |
| Total current liabilities | 7.93M | 15.11M | 6.10M | 4.07M | 3.45M |
| Net debt | -125.55M | -162.43M | -200.02M | -157.31M | -236.98M |
| Short term debt | - | 10.25M | - | - | - |
| Short long term debt | - | 10.25M | - | - | - |
| Short long term debt total | - | 10.25M | - | - | - |
| Other stockholder equity | - | - | - | 0.83M | 1.97M |
| Property plant equipment | - | - | - | 26.26M | 28.31M |
| Total current assets | 126.95M | 174.57M | 201.72M | 219.84M | 246.87M |
| Net tangible assets | - | - | - | 240.40M | 269.38M |
| Short term investments | - | - | 0.00M | 60.17M | - |
| Net receivables | 0.36M | 0.86M | 0.94M | 1.76M | 8.95M |
| Inventory | - | - | - | - | -8.95M |
| Accounts payable | 1.53M | 2.22M | 2.52M | 2.41M | 2.07M |
| Accumulated other comprehensive income | - | - | 0.00M | 0.83M | 1.97M |
| Common stock total equity | - | - | - | 267.32M | 262.26M |
| Retained earnings total equity | - | - | - | -27.75M | 5.15M |
| Non current assets total | 23.13M | 24.53M | 25.52M | 26.26M | 28.31M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -1.30M | 57.70M | -63.31M | -3.52M |
| Change to liabilities | - | - | - | 0.74M | -0.28M |
| Total cashflows from investing activities | -0.29M | -1.30M | 61.50M | -63.89M | -3.52M |
| Net borrowings | -10.25M | 10.25M | 0.00M | - | - |
| Total cash from financing activities | -10.25M | 10.45M | -0.01M | 0.00M | -67.01M |
| Change to operating activities | - | - | - | -0.65M | 76.91M |
| Net income | -45.54M | -38.53M | -24.56M | -32.90M | -17.41M |
| Change in cash | -47.13M | -27.35M | 42.72M | -79.68M | -0.38M |
| Begin period cash flow | 172.68M | 200.02M | 157.31M | 236.98M | 237.37M |
| End period cash flow | 125.55M | 172.68M | 200.02M | 157.31M | 236.98M |
| Total cash from operating activities | -39.92M | -30.96M | -18.73M | -14.82M | 69.44M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 1.69M | 1.75M | 1.74M | 2.61M | 2.65M |
| Other cashflows from investing activities | - | - | 61.86M | - | - |
| Dividends paid | - | - | - | 0.00M | -75.00M |
| Change to inventory | - | - | - | - | -2.50M |
| Change to account receivables | 0.57M | 0.08M | 0.83M | 0.00M | 4.11M |
| Sale purchase of stock | - | - | - | - | 8.00M |
| Other cashflows from financing activities | -10.25M | 0.20M | -0.01M | -63.89M | 428.00M |
| Change to netincome | - | - | - | 7.86M | 4.46M |
| Capital expenditures | 0.29M | 1.30M | 0.36M | 0.58M | 3.52M |
| Change receivables | - | - | - | -1.22M | 4.11M |
| Cash flows other operating | - | - | - | 8.07M | 75.91M |
| Cash and cash equivalents changes | - | - | - | -78.72M | -1.09M |
| Change in working capital | 3.64M | -1.46M | 2.72M | 7.60M | 79.75M |
| Stock based compensation | 3.62M | 1.75M | 3.26M | 5.06M | 4.46M |
| Other non cash items | -3.33M | 5.53M | -1.89M | 3.62M | 0.09M |
| Free cash flow | -40.21M | -32.27M | -19.09M | -15.41M | 65.92M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| XBIT XBiotech Inc |
-0.08 4.02% |
1.91 | - | - | 12.23 | 0.52 | 24.05 | -1.60 |
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-0.14 0.02% |
813.12 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. John Simard | Founder, Pres, CEO & Chairman | 1962 |
| Ms. Queena Han B.A., C.G.A., CPA, CPA | VP of Fin. & HR and Sec. | 1967 |
| Dr. Sushma Shivaswamy Ph.D. | Chief Scientific Officer | 1978 |
| Mr. Benjamín Guzmán | Sr. VP of Corp. Strategy & Fin. | 1956 |
| Ms. Lisa Simard | Director of Corp. Strategy - XBiotech USA, Inc. | NA |
| Mr. John Simard | Founder, President, CEO & Chairman | 1962 |
| Ms. Angela Hu | Director of Finance, Principal Financial & Accounting Officer and Financial Controller | 1984 |
| Mr. John Simard | Founder & Chairman | 1962 |
| Dr. Sushma Shivaswamy Ph.D. | Interim CEO & Chief Scientific Officer | 1978 |
| Ms. Angela Hu | Director of Finance | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.49%
Communication Services
+0.04%
Consumer Cyclical
+0.85%
Consumer Defensive
-0.18%
Energy
-0.08%
Financial Services
+0.51%
Financials
-2.62%
Healthcare
+0.41%
Industrials
+0.58%
Real Estate
+0.42%
Technology
-0.56%
Utilities
+0.40%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...